Evotec SE (NASDAQ:EVO) Short Interest Up 89.9% in January

Evotec SE (NASDAQ:EVO) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 766,200 shares, an increase of 89.9% from the December 31st total of 403,500 shares. Based on an average trading volume of 232,100 shares, the days-to-cover ratio is currently 3.3 days. Approximately 0.3% of the company’s stock are sold short.

Evotec Stock Up 0.5 %

Shares of Evotec stock traded up $0.02 on Wednesday, hitting $4.22. The stock had a trading volume of 20,658 shares, compared to its average volume of 52,542. Evotec has a twelve month low of $2.85 and a twelve month high of $7.98. The business’s 50 day moving average is $4.48 and its two-hundred day moving average is $4.05. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.

Hedge Funds Weigh In On Evotec

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Evotec in the second quarter valued at approximately $87,000. Clear Harbor Asset Management LLC bought a new stake in shares of Evotec in the third quarter valued at approximately $104,000. Mediolanum International Funds Ltd bought a new stake in shares of Evotec in the third quarter valued at approximately $512,000. Finally, Wellington Management Group LLP boosted its stake in shares of Evotec by 29.7% in the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock valued at $9,616,000 after buying an additional 602,858 shares during the period. Institutional investors and hedge funds own 5.81% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on EVO. Jefferies Financial Group downgraded Evotec from a “buy” rating to a “hold” rating and lowered their price target for the stock from $8.70 to $3.80 in a research report on Monday, October 7th. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Evotec in a research report on Thursday, November 7th.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.